RxDoctor Payments Data

Lucy Palomino

Family · Bronx, NYNPI 1871611319

Payments from drug & device makers

$2,748in general payments, 2019–2025

Across 95 payments — averaging $28.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$268
  • Janssen Products, LP$198
  • Johnson & Johnson$175
  • AbbVie$164
  • Exact Sciences$99
  • plus $209 from 6 others

What the payments were for

  • Food & beverage$2,55093%
  • Education$1987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,748 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$3,275
Medicare patients
15
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin259$240,512
BiktarvyBictegrav/Emtricit/Tenofov Ala44$167,539
DovatoDolutegravir Sodium/Lamivudine23$64,078
Janumet XrSitagliptin Phos/Metformin Hcl64$51,260
OzempicSemaglutide42$38,161
JanumetSitagliptin Phos/Metformin Hcl27$22,774
Tresiba Flextouch U-200Insulin Degludec38$19,285
ProliaDenosumab11$17,747
TradjentaLinagliptin11$16,390
TrulicityDulaglutide16$14,636
EliquisApixaban12$13,174
RybelsusSemaglutide13$12,663
JentaduetoLinagliptin/Metformin Hcl19$12,170
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$8,380
BrilintaTicagrelor14$6,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$268$167,53944 claims
MerckJanumet Xr, Janumet$23$74,03591 claims
Viiv Healthcare CompanyDovato$1,634$64,07823 claims
Lilly USA, LLCTrulicity$13$14,63616 claims
AstraZenecaBrilinta$39$6,69214 claims
GSKBreo Ellipta$33$5,33414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →